

TDMS No. 99032 - 04
Test Type: CHRONIC
Route: SKIN APPLICATION
Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)
Pyrogallol
CAS Number: 87-66-1

Date Report Requested: 08/17/2010
Time Report Requested: 13:34:47
First Dose M/F: 09/21/04 / 09/20/04
Lab: BAT

F1_M3

C Number: C99032
Lock Date: 03/04/2008
Cage Range: ALL
Date Range: ALL
Reasons For Removal: ALL
Removal Date Range: ALL
Treatment Groups: Include ALL
Study Gender: Both
TDMSE Version: 2.2.0

TDMS No. 99032 - 04
 Test Type: CHRONIC
 Route: SKIN APPLICATION
 Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)
 Pyrogallol
 CAS Number: 87-66-1

Date Report Requested: 08/17/2010
 Time Report Requested: 13:34:47
 First Dose M/F: 09/21/04 / 09/20/04
 Lab: BAT

B6C3F1 MICE MALE	0 MG/KG	5 MG/KG	20 MG/KG	75 MG/KG
------------------	---------	---------	----------	----------

Disposition Summary

Animals Initially In Study	50	50	50	50
Early Deaths				
Accidentally Killed				1
Moribund Sacrifice	8	10	10	12
Natural Death	5	4	6	6
Survivors				
Terminal Sacrifice	37	36	34	31
Animals Examined Microscopically	50	50	50	50

ALIMENTARY SYSTEM

Esophagus	(50)	(50)	(50)	(50)
Inflammation				1 (2%)
Epithelium, Cyst				1 (2%)
Gallbladder	(49)	(49)	(50)	(46)
Cyst	1 (2%)			
Infiltration Cellular, Mononuclear Cell	4 (8%)	8 (16%)	4 (8%)	3 (7%)
Epithelium, Hyperplasia	1 (2%)		1 (2%)	
Intestine Large, Cecum	(50)	(50)	(50)	(50)
Hyperplasia, Lymphoid			1 (2%)	
Inflammation			1 (2%)	
Epithelium, Hyperplasia				1 (2%)
Intestine Large, Colon	(50)	(50)	(50)	(50)
Intestine Large, Rectum	(50)	(50)	(50)	(50)
Inflammation			1 (2%)	
Epithelium, Hyperplasia			2 (4%)	
Muscularis, Hypertrophy			1 (2%)	
Intestine Small, Duodenum	(50)	(50)	(50)	(50)
Inflammation		1 (2%)		
Epithelium, Hyperplasia		1 (2%)		
Intestine Small, Ileum	(50)	(50)	(50)	(50)
Inflammation		2 (4%)	5 (10%)	
Epithelium, Hyperplasia		2 (4%)	2 (4%)	
Intestine Small, Jejunum	(50)	(50)	(50)	(50)

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 99032 - 04
 Test Type: CHRONIC
 Route: SKIN APPLICATION
 Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)
 Pyrogallol
 CAS Number: 87-66-1

Date Report Requested: 08/17/2010
 Time Report Requested: 13:34:47
 First Dose M/F: 09/21/04 / 09/20/04
 Lab: BAT

B6C3F1 MICE MALE	0 MG/KG	5 MG/KG	20 MG/KG	75 MG/KG
Cyst				1 (2%)
Hyperplasia, Lymphoid	9 (18%)	5 (10%)	5 (10%)	
Inflammation	1 (2%)	2 (4%)	3 (6%)	
Inflammation, Granulomatous Epithelium, Hyperplasia	1 (2%)	1 (2%)		1 (2%)
Liver	(50)	(50)	(50)	(50)
Angiectasis			1 (2%)	
Atypia Cellular				1 (2%)
Basophilic Focus	5 (10%)	7 (14%)	7 (14%)	7 (14%)
Clear Cell Focus	29 (58%)	31 (62%)	29 (58%)	23 (46%)
Cytoplasmic Alteration		1 (2%)	1 (2%)	
Degeneration, Fatty		1 (2%)		
Eosinophilic Focus	31 (62%)	32 (64%)	31 (62%)	26 (52%)
Fibrosis	1 (2%)			
Hematopoietic Cell Proliferation		4 (8%)	4 (8%)	14 (28%)
Hepatodiaphragmatic Nodule	2 (4%)			
Infarct			1 (2%)	
Inflammation	31 (62%)	25 (50%)	29 (58%)	24 (48%)
Metaplasia, Osseous	1 (2%)			
Mixed Cell Focus	5 (10%)	5 (10%)	6 (12%)	
Necrosis	5 (10%)	3 (6%)	1 (2%)	4 (8%)
Pigmentation	2 (4%)		1 (2%)	2 (4%)
Regeneration	1 (2%)			
Tension Lipidosis	2 (4%)	3 (6%)	4 (8%)	2 (4%)
Thrombosis		1 (2%)		
Vacuolization Cytoplasmic	10 (20%)	23 (46%)	19 (38%)	6 (12%)
Bile Duct, Cyst				3 (6%)
Bile Duct, Hyperplasia	2 (4%)	1 (2%)	3 (6%)	2 (4%)
Hepatocyte, Hypertrophy	1 (2%)			
Kupffer Cell, Hyperplasia	1 (2%)			1 (2%)
Kupffer Cell, Pigmentation	1 (2%)			
Oval Cell, Hyperplasia	2 (4%)		1 (2%)	1 (2%)
Mesentery	(8)	(6)	(8)	(10)
Inflammation	3 (38%)	1 (17%)	2 (25%)	2 (20%)
Fat, Necrosis	4 (50%)	2 (33%)	3 (38%)	3 (30%)
Oral Mucosa	(0)	(0)	(0)	(1)

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 99032 - 04
 Test Type: CHRONIC
 Route: SKIN APPLICATION
 Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)
 Pyrogallol
 CAS Number: 87-66-1

Date Report Requested: 08/17/2010
 Time Report Requested: 13:34:47
 First Dose M/F: 09/21/04 / 09/20/04
 Lab: BAT

B6C3F1 MICE MALE	0 MG/KG	5 MG/KG	20 MG/KG	75 MG/KG
Pancreas	(50)	(50)	(50)	(50)
Cytoplasmic Alteration, Focal	1 (2%)			
Hemorrhage		1 (2%)		
Infiltration Cellular, Mononuclear Cell	9 (18%)	14 (28%)	15 (30%)	9 (18%)
Inflammation	2 (4%)			1 (2%)
Pigmentation				1 (2%)
Vacuolization Cytoplasmic	1 (2%)			
Acinus, Atrophy	2 (4%)	2 (4%)	1 (2%)	
Duct, Cyst	1 (2%)			1 (2%)
Salivary Glands	(50)	(50)	(50)	(50)
Atrophy		1 (2%)	1 (2%)	
Infiltration Cellular, Mononuclear Cell	40 (80%)	40 (80%)	41 (82%)	40 (80%)
Inflammation				2 (4%)
Mineralization	1 (2%)	1 (2%)	2 (4%)	
Duct, Hyperplasia			1 (2%)	
Submandibular Gland, Vacuolization Cytoplasmic	1 (2%)			
Stomach, Forestomach	(50)	(50)	(50)	(50)
Hyperplasia		1 (2%)		
Inflammation	2 (4%)	5 (10%)	3 (6%)	5 (10%)
Ulcer	2 (4%)			2 (4%)
Epithelium, Cyst			1 (2%)	
Epithelium, Hyperkeratosis	4 (8%)	3 (6%)	6 (12%)	5 (10%)
Epithelium, Hyperplasia, Squamous	3 (6%)	5 (10%)	6 (12%)	7 (14%)
Stomach, Glandular	(50)	(50)	(50)	(50)
Cyst	6 (12%)	19 (38%)	14 (28%)	10 (20%)
Foreign Body		1 (2%)		
Hyperplasia	5 (10%)	5 (10%)	1 (2%)	5 (10%)
Infiltration Cellular, Mononuclear Cell		4 (8%)	2 (4%)	
Inflammation		1 (2%)	5 (10%)	
Inflammation, Granulomatous			1 (2%)	
Mineralization	1 (2%)	2 (4%)		
Tooth	(36)	(30)	(24)	(22)
Dysplasia	35 (97%)	27 (90%)	21 (88%)	21 (95%)

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 99032 - 04
 Test Type: CHRONIC
 Route: SKIN APPLICATION
 Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)
 Pyrogallol
 CAS Number: 87-66-1

Date Report Requested: 08/17/2010
 Time Report Requested: 13:34:47
 First Dose M/F: 09/21/04 / 09/20/04
 Lab: BAT

B6C3F1 MICE MALE	0 MG/KG	5 MG/KG	20 MG/KG	75 MG/KG
CARDIOVASCULAR SYSTEM				
Blood Vessel	(50)	(50)	(50)	(50)
Aorta, Infiltration Cellular, Mononuclear Cell		1 (2%)		
Aorta, Mineralization		1 (2%)		
Carotid Artery, Inflammation	1 (2%)		3 (6%)	
Carotid Artery, Thrombosis			1 (2%)	
Heart	(50)	(50)	(50)	(50)
Cardiomyopathy	45 (90%)	44 (88%)	46 (92%)	44 (88%)
Infiltration Cellular, Mononuclear Cell	1 (2%)	2 (4%)	1 (2%)	4 (8%)
Inflammation	2 (4%)	5 (10%)	4 (8%)	2 (4%)
Metaplasia, Osseous		1 (2%)		
Mineralization	1 (2%)		2 (4%)	2 (4%)
Necrosis	1 (2%)			
Thrombosis	1 (2%)			
ENDOCRINE SYSTEM				
Adrenal Cortex	(50)	(50)	(50)	(50)
Angiectasis		2 (4%)	2 (4%)	1 (2%)
Fibrosis	1 (2%)			
Hematopoietic Cell Proliferation				2 (4%)
Hyperplasia	1 (2%)			
Hypertrophy	15 (30%)	18 (36%)	13 (26%)	8 (16%)
Inflammation		1 (2%)		
Mineralization			1 (2%)	
Vacuolization Cytoplasmic			1 (2%)	
Subcapsular, Hyperplasia	40 (80%)	39 (78%)	44 (88%)	44 (88%)
Adrenal Medulla	(50)	(50)	(50)	(50)
Hyperplasia			1 (2%)	
Islets, Pancreatic	(50)	(50)	(50)	(50)
Hyperplasia	43 (86%)	43 (86%)	42 (84%)	40 (80%)
Parathyroid Gland	(41)	(44)	(42)	(47)
Hyperplasia	1 (2%)			
Pituitary Gland	(50)	(50)	(50)	(50)

a - Number of animals examined microscopically at site and number of animals with lesion

B6C3F1 MICE MALE	0 MG/KG	5 MG/KG	20 MG/KG	75 MG/KG
Inflammation	1 (2%)			
Pars Distalis, Hyperplasia	2 (4%)	1 (2%)	2 (4%)	1 (2%)
Pars Intermedia, Hyperplasia			1 (2%)	
Thyroid Gland	(50)	(50)	(50)	(50)
Follicular Cell, Hyperplasia			1 (2%)	

GENERAL BODY SYSTEM

Peritoneum	(0)	(1)	(1)	(1)
Hyperplasia			1 (100%)	
Inflammation		1 (100%)		1 (100%)

GENITAL SYSTEM

Coagulating Gland	(0)	(2)	(1)	(0)
Epididymis	(50)	(50)	(50)	(50)
Fibrosis	1 (2%)		2 (4%)	
Granuloma Sperm		2 (4%)		1 (2%)
Infiltration Cellular, Mononuclear Cell	37 (74%)	38 (76%)	39 (78%)	33 (66%)
Inflammation	3 (6%)	4 (8%)	1 (2%)	2 (4%)
Inflammation, Granulomatous		1 (2%)		
Mineralization			1 (2%)	
Pigmentation		1 (2%)		
Artery, Inflammation		1 (2%)		
Epithelium, Hyperplasia				1 (2%)
Penis	(1)	(0)	(0)	(0)
Inflammation	1 (100%)			
Preputial Gland	(50)	(50)	(50)	(50)
Cyst				1 (2%)
Ectasia	3 (6%)	3 (6%)	5 (10%)	2 (4%)
Infiltration Cellular, Mononuclear Cell	20 (40%)	22 (44%)	22 (44%)	26 (52%)
Inflammation	12 (24%)	21 (42%)	14 (28%)	11 (22%)
Prostate	(50)	(50)	(50)	(50)
Fibrosis		1 (2%)		
Hyperplasia	12 (24%)	21 (42%)	15 (30%)	19 (38%)

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Pyrogallol

Time Report Requested: 13:34:47

Route: SKIN APPLICATION

CAS Number: 87-66-1

First Dose M/F: 09/21/04 / 09/20/04

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE MALE	0 MG/KG	5 MG/KG	20 MG/KG	75 MG/KG
Hypertrophy	1 (2%)			
Infiltration Cellular, Mononuclear Cell	42 (84%)	44 (88%)	43 (86%)	38 (76%)
Inflammation	1 (2%)	4 (8%)	4 (8%)	3 (6%)
Artery, Inflammation		1 (2%)		
Seminal Vesicle	(50)	(50)	(50)	(50)
Infiltration Cellular, Mixed Cell	1 (2%)			
Infiltration Cellular, Mononuclear Cell	8 (16%)	12 (24%)	19 (38%)	14 (28%)
Inflammation		5 (10%)	1 (2%)	1 (2%)
Bilateral, Dilatation	1 (2%)	2 (4%)		
Testes	(50)	(50)	(50)	(50)
Atrophy	1 (2%)		1 (2%)	
Infiltration Cellular, Mononuclear Cell	1 (2%)		2 (4%)	
Mineralization		1 (2%)		1 (2%)

HEMATOPOIETIC SYSTEM

Bone Marrow	(50)	(50)	(50)	(50)
Hyperplasia	3 (6%)	10 (20%)	8 (16%)	15 (30%)
Lymph Node	(10)	(12)	(9)	(16)
Axillary, Hyperplasia, Lymphoid			1 (11%)	3 (19%)
Bronchial, Hyperplasia, Lymphoid	1 (10%)	2 (17%)	1 (11%)	
Inguinal, Hyperplasia, Lymphoid	6 (60%)	6 (50%)	8 (89%)	10 (63%)
Inguinal, Pigmentation		1 (8%)		
Mediastinal, Hyperplasia, Lymphoid				3 (19%)
Mediastinal, Inflammation				1 (6%)
Renal, Necrosis				1 (6%)
Lymph Node, Mandibular	(50)	(50)	(50)	(50)
Hematopoietic Cell Proliferation				1 (2%)
Hyperplasia, Lymphoid	9 (18%)	16 (32%)	12 (24%)	11 (22%)
Inflammation				1 (2%)
Lymph Node, Mesenteric	(50)	(49)	(50)	(49)
Angiectasis			1 (2%)	
Hyperplasia, Lymphoid	5 (10%)	7 (14%)	10 (20%)	3 (6%)
Inflammation	1 (2%)		1 (2%)	1 (2%)
Pigmentation	1 (2%)			

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 99032 - 04
 Test Type: CHRONIC
 Route: SKIN APPLICATION
 Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)
 Pyrogallol
 CAS Number: 87-66-1

Date Report Requested: 08/17/2010
 Time Report Requested: 13:34:47
 First Dose M/F: 09/21/04 / 09/20/04
 Lab: BAT

B6C3F1 MICE MALE	0 MG/KG	5 MG/KG	20 MG/KG	75 MG/KG
Spleen	(50)	(49)	(50)	(50)
Angiectasis				1 (2%)
Hematopoietic Cell Proliferation	37 (74%)	38 (78%)	40 (80%)	42 (84%)
Hyperplasia, Lymphoid	5 (10%)	2 (4%)	3 (6%)	5 (10%)
Inflammation				1 (2%)
Pigmentation			1 (2%)	
Thymus	(48)	(50)	(46)	(48)
Hyperplasia, Lymphoid	2 (4%)	2 (4%)	1 (2%)	1 (2%)
INTEGUMENTARY SYSTEM				
Mammary Gland	(0)	(0)	(0)	(1)
Hyperplasia				1 (100%)
Skin	(50)	(50)	(50)	(50)
Abscess		1 (2%)		
Fibrosis	1 (2%)	1 (2%)	3 (6%)	10 (20%)
Hyperkeratosis	1 (2%)	1 (2%)	3 (6%)	10 (20%)
Hyperplasia	1 (2%)	1 (2%)	3 (6%)	10 (20%)
Inflammation	1 (2%)	1 (2%)	3 (6%)	10 (20%)
Metaplasia, Cartilagenous				1 (2%)
Ulcer		1 (2%)	3 (6%)	10 (20%)
Control, Inflammation			1 (2%)	1 (2%)
Hair Follicle, Site Of Application, Cyst				1 (2%)
Lip, Inflammation		1 (2%)		
Sebaceous Gland, Hyperplasia	1 (2%)	1 (2%)		5 (10%)
Sebaceous Gland, Site Of Application, Hyperplasia	1 (2%)	6 (12%)	4 (8%)	24 (48%)
Site Of Application, Fibrosis	3 (6%)	6 (12%)	28 (56%)	47 (94%)
Site Of Application, Hyperkeratosis	11 (22%)	43 (86%)	50 (100%)	50 (100%)
Site Of Application, Hyperplasia	8 (16%)	24 (48%)	47 (94%)	50 (100%)
Site Of Application, Inflammation	2 (4%)	6 (12%)	37 (74%)	44 (88%)
Site Of Application, Pigmentation			9 (18%)	39 (78%)
Site Of Application, Ulcer	1 (2%)	1 (2%)	2 (4%)	23 (46%)

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 99032 - 04
 Test Type: CHRONIC
 Route: SKIN APPLICATION
 Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)
 Pyrogallol
 CAS Number: 87-66-1

Date Report Requested: 08/17/2010
 Time Report Requested: 13:34:47
 First Dose M/F: 09/21/04 / 09/20/04
 Lab: BAT

B6C3F1 MICE MALE	0 MG/KG	5 MG/KG	20 MG/KG	75 MG/KG
MUSCULOSKELETAL SYSTEM				
Bone	(50)	(50)	(50)	(50)
Cranium, Hyperostosis			1 (2%)	1 (2%)
Cranium, Inflammation	1 (2%)			1 (2%)
Skeletal Muscle	(0)	(0)	(1)	(2)
Inflammation			1 (100%)	
Mineralization				1 (50%)
NERVOUS SYSTEM				
Brain	(50)	(50)	(50)	(50)
Developmental Malformation	1 (2%)			
Infiltration Cellular, Mononuclear Cell	4 (8%)	2 (4%)		1 (2%)
Inflammation	1 (2%)			1 (2%)
Cerebellum, Gliosis				1 (2%)
Choroid Plexus, Mineralization	1 (2%)			
RESPIRATORY SYSTEM				
Lung	(50)	(50)	(50)	(50)
Infiltration Cellular, Histiocyte	5 (10%)	12 (24%)	7 (14%)	6 (12%)
Inflammation	7 (14%)	3 (6%)	5 (10%)	3 (6%)
Metaplasia, Osseous		1 (2%)		2 (4%)
Mineralization		1 (2%)	1 (2%)	
Pigmentation	1 (2%)	3 (6%)	2 (4%)	
Thrombosis			1 (2%)	
Alveolar Epithelium, Hyperplasia	7 (14%)	3 (6%)	3 (6%)	5 (10%)
Bronchiole, Hyperplasia		1 (2%)		1 (2%)
Bronchiole, Mineralization	1 (2%)			
Interstitialium, Fibrosis			1 (2%)	
Mediastinum, Necrosis, Fatty				1 (2%)
Nose	(50)	(50)	(50)	(50)
Foreign Body			1 (2%)	

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 99032 - 04
 Test Type: CHRONIC
 Route: SKIN APPLICATION
 Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)
 Pyrogallol
 CAS Number: 87-66-1

Date Report Requested: 08/17/2010
 Time Report Requested: 13:34:47
 First Dose M/F: 09/21/04 / 09/20/04
 Lab: BAT

B6C3F1 MICE MALE	0 MG/KG	5 MG/KG	20 MG/KG	75 MG/KG
Inflammation	20 (40%)	15 (30%)	16 (32%)	15 (30%)
Necrosis				1 (2%)
Polyp, Inflammatory	2 (4%)	2 (4%)	2 (4%)	1 (2%)
Glands, Dilatation	2 (4%)		1 (2%)	2 (4%)
Glands, Fibrosis	1 (2%)			
Glands, Metaplasia	11 (22%)	3 (6%)	1 (2%)	3 (6%)
Goblet Cell, Hyperplasia				2 (4%)
Olfactory Epithelium, Degeneration	2 (4%)			3 (6%)
Olfactory Epithelium, Hyperplasia	1 (2%)	1 (2%)	1 (2%)	
Olfactory Epithelium, Metaplasia	11 (22%)	8 (16%)	4 (8%)	5 (10%)
Respiratory Epithelium, Degeneration	2 (4%)		1 (2%)	
Respiratory Epithelium, Hyperplasia	40 (80%)	45 (90%)	46 (92%)	37 (74%)
Respiratory Epithelium, Metaplasia	2 (4%)	1 (2%)		1 (2%)
Vomeranasal Organ, Cyst			1 (2%)	

SPECIAL SENSES SYSTEM

Eye	(50)	(50)	(50)	(50)
Cataract			1 (2%)	1 (2%)
Developmental Malformation			1 (2%)	
Infiltration Cellular, Mononuclear Cell			1 (2%)	
Inflammation	4 (8%)	2 (4%)	3 (6%)	1 (2%)
Cornea, Hyperplasia	2 (4%)	1 (2%)		1 (2%)
Harderian Gland	(50)	(50)	(50)	(50)
Cyst	1 (2%)			
Hyperplasia	3 (6%)	1 (2%)	1 (2%)	3 (6%)
Infiltration Cellular, Mononuclear Cell	35 (70%)	41 (82%)	41 (82%)	36 (72%)
Inflammation	1 (2%)			1 (2%)

URINARY SYSTEM

Kidney	(50)	(50)	(50)	(50)
Accumulation, Hyaline Droplet				1 (2%)
Cyst		5 (10%)	9 (18%)	4 (8%)
Dilatation		2 (4%)		

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 99032 - 04
 Test Type: CHRONIC
 Route: SKIN APPLICATION
 Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)
 Pyrogallol
 CAS Number: 87-66-1

Date Report Requested: 08/17/2010
 Time Report Requested: 13:34:47
 First Dose M/F: 09/21/04 / 09/20/04
 Lab: BAT

B6C3F1 MICE MALE	0 MG/KG	5 MG/KG	20 MG/KG	75 MG/KG
Hyperplasia, Oncocytic				1 (2%)
Infarct		1 (2%)		
Infiltration Cellular, Mononuclear Cell	2 (4%)		5 (10%)	4 (8%)
Inflammation	1 (2%)	3 (6%)	2 (4%)	2 (4%)
Metaplasia, Osseous	6 (12%)	2 (4%)		
Mineralization	39 (78%)	42 (84%)	34 (68%)	38 (76%)
Nephropathy	44 (88%)	46 (92%)	47 (94%)	45 (90%)
Pigmentation	1 (2%)			1 (2%)
Thrombosis	1 (2%)	1 (2%)		
Papilla, Necrosis		1 (2%)		
Renal Tubule, Hyperplasia	3 (6%)	2 (4%)	1 (2%)	1 (2%)
Urethra	(0)	(1)	(1)	(1)
Inflammation		1 (100%)		1 (100%)
Bulbourethral Gland, Inflammation		1 (100%)	1 (100%)	
Bulbourethral Gland, Necrosis		1 (100%)		
Transitional Epithelium, Hyperplasia		1 (100%)		
Urinary Bladder	(50)	(50)	(50)	(50)
Infiltration Cellular, Mononuclear Cell	20 (40%)	31 (62%)	33 (66%)	23 (46%)
Inflammation		1 (2%)	2 (4%)	

*** END OF MALE ***

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 99032 - 04
 Test Type: CHRONIC
 Route: SKIN APPLICATION
 Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)
 Pyrogallol
 CAS Number: 87-66-1

Date Report Requested: 08/17/2010
 Time Report Requested: 13:34:47
 First Dose M/F: 09/21/04 / 09/20/04
 Lab: BAT

B6C3F1 MICE FEMALE	0 MG/KG	5 MG/KG	20 MG/KG	75 MG/KG
--------------------	---------	---------	----------	----------

Disposition Summary

Animals Initially In Study	50	50	50	50
Early Deaths				
Moribund Sacrifice	9	15	7	29
Natural Death	8	5	7	4
Survivors				
Natural Death				1
Terminal Sacrifice	33	30	36	16
Animals Examined Microscopically	50	50	50	50

ALIMENTARY SYSTEM

Esophagus	(50)	(50)	(50)	(50)
Inflammation			1 (2%)	
Epithelium, Hyperplasia			1 (2%)	
Gallbladder	(50)	(49)	(49)	(50)
Cyst	1 (2%)			1 (2%)
Infiltration Cellular, Mononuclear Cell	4 (8%)	7 (14%)	6 (12%)	6 (12%)
Inflammation	1 (2%)			
Epithelium, Hyperplasia		1 (2%)		
Intestine Large, Cecum	(50)	(50)	(50)	(50)
Inflammation	1 (2%)			
Epithelium, Hyperplasia		1 (2%)		
Intestine Large, Colon	(50)	(50)	(50)	(50)
Artery, Inflammation				1 (2%)
Intestine Large, Rectum	(50)	(50)	(50)	(50)
Artery, Inflammation				1 (2%)
Epithelium, Hyperplasia			1 (2%)	
Intestine Small, Duodenum	(50)	(50)	(50)	(50)
Inflammation	1 (2%)			
Epithelium, Hyperplasia			1 (2%)	
Intestine Small, Ileum	(50)	(50)	(50)	(50)
Inflammation	1 (2%)	1 (2%)		1 (2%)
Epithelium, Hyperplasia	1 (2%)	1 (2%)	3 (6%)	
Intestine Small, Jejunum	(50)	(50)	(50)	(50)

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 99032 - 04
 Test Type: CHRONIC
 Route: SKIN APPLICATION
 Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)
 Pyrogallol
 CAS Number: 87-66-1

Date Report Requested: 08/17/2010
 Time Report Requested: 13:34:47
 First Dose M/F: 09/21/04 / 09/20/04
 Lab: BAT

B6C3F1 MICE FEMALE	0 MG/KG	5 MG/KG	20 MG/KG	75 MG/KG
Hyperplasia, Lymphoid Inflammation Epithelium, Hyperplasia	2 (4%)	5 (10%)	2 (4%) 2 (4%) 1 (2%)	2 (4%)
Liver	(50)	(50)	(50)	(50)
Angiectasis	2 (4%)		2 (4%)	
Atrophy			1 (2%)	
Basophilic Focus	8 (16%)	2 (4%)	3 (6%)	2 (4%)
Clear Cell Focus	10 (20%)	1 (2%)	3 (6%)	1 (2%)
Eosinophilic Focus	26 (52%)	28 (56%)	31 (62%)	12 (24%)
Fibrosis	1 (2%)	1 (2%)		
Hematopoietic Cell Proliferation	9 (18%)	8 (16%)	9 (18%)	30 (60%)
Hypertrophy, Diffuse Inflammation	40 (80%)	32 (64%)	43 (86%)	37 (74%)
Mixed Cell Focus	6 (12%)	7 (14%)	4 (8%)	1 (2%)
Necrosis	8 (16%)	5 (10%)	2 (4%)	6 (12%)
Pigmentation		1 (2%)		
Tension Lipidosis	7 (14%)	6 (12%)	7 (14%)	10 (20%)
Vacuolization Cytoplasmic Centrilobular, Hepatocyte, Degeneration	7 (14%) 1 (2%)	5 (10%)	6 (12%)	1 (2%)
Mesentery	(20)	(22)	(14)	(19)
Inflammation	2 (10%)	2 (9%)		1 (5%)
Thrombosis	1 (5%)			
Fat, Necrosis	12 (60%)	10 (45%)	11 (79%)	15 (79%)
Fat, Thrombosis		1 (5%)		
Pancreas	(50)	(50)	(50)	(50)
Atrophy				1 (2%)
Infiltration Cellular, Mononuclear Cell	31 (62%)	25 (50%)	24 (48%)	21 (42%)
Inflammation	3 (6%)			4 (8%)
Acinus, Atrophy	3 (6%)	1 (2%)	1 (2%)	2 (4%)
Artery, Inflammation		1 (2%)		
Duct, Cyst	1 (2%)			
Salivary Glands	(50)	(50)	(50)	(50)
Atrophy				1 (2%)
Infiltration Cellular, Mononuclear Cell	36 (72%)	37 (74%)	38 (76%)	30 (60%)
Inflammation			1 (2%)	1 (2%)
Mineralization		1 (2%)		2 (4%)

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 99032 - 04
 Test Type: CHRONIC
 Route: SKIN APPLICATION
 Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)
 Pyrogallol
 CAS Number: 87-66-1

Date Report Requested: 08/17/2010
 Time Report Requested: 13:34:47
 First Dose M/F: 09/21/04 / 09/20/04
 Lab: BAT

B6C3F1 MICE FEMALE	0 MG/KG	5 MG/KG	20 MG/KG	75 MG/KG
Stomach, Forestomach	(50)	(50)	(50)	(50)
Hyperplasia		1 (2%)		
Infiltration Cellular, Mononuclear Cell			1 (2%)	2 (4%)
Infiltration Cellular, Diffuse				1 (2%)
Inflammation		5 (10%)	2 (4%)	
Ulcer		3 (6%)	1 (2%)	
Epithelium, Hyperkeratosis	1 (2%)	6 (12%)	2 (4%)	1 (2%)
Epithelium, Hyperplasia, Squamous	2 (4%)	9 (18%)	3 (6%)	1 (2%)
Stomach, Glandular	(50)	(50)	(50)	(50)
Cyst	15 (30%)	18 (36%)	15 (30%)	14 (28%)
Hyperplasia	3 (6%)	1 (2%)	1 (2%)	4 (8%)
Infiltration Cellular, Mononuclear Cell	1 (2%)	4 (8%)	5 (10%)	2 (4%)
Infiltration Cellular, Diffuse				1 (2%)
Inflammation		3 (6%)	1 (2%)	1 (2%)
Mineralization			1 (2%)	2 (4%)
Necrosis		1 (2%)		
Ulcer		1 (2%)	1 (2%)	
Tooth	(3)	(0)	(4)	(0)
Dysplasia	3 (100%)		4 (100%)	

CARDIOVASCULAR SYSTEM

Blood Vessel	(50)	(50)	(50)	(50)
Inflammation	1 (2%)			
Carotid Artery, Mineralization		1 (2%)		
Heart	(50)	(50)	(50)	(50)
Cardiomyopathy	42 (84%)	33 (66%)	35 (70%)	38 (76%)
Infiltration Cellular, Mononuclear Cell	1 (2%)	3 (6%)	4 (8%)	3 (6%)
Inflammation	3 (6%)	3 (6%)	1 (2%)	2 (4%)
Mineralization	2 (4%)	4 (8%)	2 (4%)	
Thrombosis	3 (6%)	1 (2%)	1 (2%)	
Myocardium, Vacuolization Cytoplasmic			1 (2%)	

ENDOCRINE SYSTEM

a - Number of animals examined microscopically at site and number of animals with lesion

B6C3F1 MICE FEMALE	0 MG/KG	5 MG/KG	20 MG/KG	75 MG/KG
Adrenal Cortex	(50)	(50)	(50)	(50)
Angiectasis			2 (4%)	1 (2%)
Degeneration, Cystic				1 (2%)
Hematopoietic Cell Proliferation	3 (6%)	4 (8%)	4 (8%)	14 (28%)
Hyperplasia			1 (2%)	
Hypertrophy	4 (8%)	2 (4%)	5 (10%)	2 (4%)
Subcapsular, Hyperplasia	50 (100%)	49 (98%)	49 (98%)	49 (98%)
Adrenal Medulla	(50)	(50)	(50)	(50)
Hyperplasia	1 (2%)	3 (6%)	2 (4%)	2 (4%)
Hypertrophy		1 (2%)		
Islets, Pancreatic	(50)	(50)	(50)	(50)
Hyperplasia	35 (70%)	15 (30%)	12 (24%)	8 (16%)
Parathyroid Gland	(45)	(47)	(39)	(38)
Cyst			2 (5%)	1 (3%)
Hyperplasia			2 (5%)	
Pituitary Gland	(50)	(49)	(50)	(50)
Angiectasis	1 (2%)	1 (2%)		
Hemorrhage	1 (2%)		1 (2%)	1 (2%)
Pars Distalis, Degeneration				1 (2%)
Pars Distalis, Hyperplasia	17 (34%)	18 (37%)	19 (38%)	17 (34%)
Thyroid Gland	(50)	(50)	(50)	(50)
Infiltration Cellular, Mononuclear Cell	1 (2%)		2 (4%)	2 (4%)
Follicular Cell, Hyperplasia		1 (2%)		

GENERAL BODY SYSTEM

Peritoneum	(1)	(0)	(0)	(0)
Inflammation	1 (100%)			
Tissue NOS	(1)	(0)	(0)	(0)

GENITAL SYSTEM

Clitoral Gland	(49)	(50)	(50)	(49)
Infiltration Cellular, Mononuclear Cell		2 (4%)	2 (4%)	1 (2%)
Inflammation	10 (20%)	10 (20%)	8 (16%)	9 (18%)

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 99032 - 04
 Test Type: CHRONIC
 Route: SKIN APPLICATION
 Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)
 Pyrogallol
 CAS Number: 87-66-1

Date Report Requested: 08/17/2010
 Time Report Requested: 13:34:47
 First Dose M/F: 09/21/04 / 09/20/04
 Lab: BAT

B6C3F1 MICE FEMALE	0 MG/KG	5 MG/KG	20 MG/KG	75 MG/KG
Ovary	(50)	(50)	(50)	(50)
Angiectasis		1 (2%)	2 (4%)	
Cyst	7 (14%)	15 (30%)	13 (26%)	14 (28%)
Infiltration Cellular, Mononuclear Cell		5 (10%)	6 (12%)	
Inflammation	2 (4%)		2 (4%)	1 (2%)
Mineralization	1 (2%)			1 (2%)
Necrosis	1 (2%)			
Pigmentation	1 (2%)			
Thrombosis		1 (2%)		
Germinal Epithelium, Hyperplasia		1 (2%)	1 (2%)	1 (2%)
Oviduct	(1)	(0)	(0)	(0)
Infiltration Cellular, Mononuclear Cell	1 (100%)			
Uterus	(50)	(50)	(50)	(50)
Angiectasis	1 (2%)		1 (2%)	
Inflammation	7 (14%)	6 (12%)	8 (16%)	4 (8%)
Pigmentation		1 (2%)		
Thrombosis	3 (6%)		1 (2%)	1 (2%)
Ulcer		2 (4%)	1 (2%)	
Cervix, Hyperplasia, Cystic				1 (2%)
Endometrium, Hyperplasia, Cystic	46 (92%)	46 (92%)	46 (92%)	43 (86%)

HEMATOPOIETIC SYSTEM

Bone Marrow	(50)	(50)	(50)	(50)
Hyperplasia	10 (20%)	14 (28%)	10 (20%)	31 (62%)
Lymph Node	(19)	(13)	(18)	(29)
Axillary, Hyperplasia, Lymphoid				8 (28%)
Axillary, Inflammation				1 (3%)
Axillary, Pigmentation				1 (3%)
Bronchial, Hyperplasia, Lymphoid	4 (21%)	1 (8%)	5 (28%)	5 (17%)
Inguinal, Hyperplasia, Lymphoid	4 (21%)	2 (15%)	7 (39%)	17 (59%)
Inguinal, Inflammation, Granulomatous	1 (5%)			
Lumbar, Angiectasis			1 (6%)	
Lumbar, Hyperplasia, Lymphoid	2 (11%)		1 (6%)	
Lumbar, Inflammation	1 (5%)			

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 99032 - 04
 Test Type: CHRONIC
 Route: SKIN APPLICATION
 Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)
 Pyrogallol
 CAS Number: 87-66-1

Date Report Requested: 08/17/2010
 Time Report Requested: 13:34:47
 First Dose M/F: 09/21/04 / 09/20/04
 Lab: BAT

B6C3F1 MICE FEMALE	0 MG/KG	5 MG/KG	20 MG/KG	75 MG/KG
Mediastinal, Hyperplasia, Lymphoid		2 (15%)	1 (6%)	
Mediastinal, Infiltration Cellular, Histiocyte	1 (5%)			
Pancreatic, Hyperplasia, Lymphoid			2 (11%)	
Renal, Angiectasis			1 (6%)	
Renal, Hyperplasia, Lymphoid	1 (5%)			1 (3%)
Lymph Node, Mandibular	(50)	(50)	(50)	(50)
Hyperplasia, Lymphoid	14 (28%)	19 (38%)	23 (46%)	27 (54%)
Inflammation				1 (2%)
Pigmentation				1 (2%)
Lymph Node, Mesenteric	(50)	(50)	(50)	(50)
Atrophy			2 (4%)	
Hematopoietic Cell Proliferation				1 (2%)
Hyperplasia, Lymphoid	13 (26%)	12 (24%)	13 (26%)	4 (8%)
Inflammation	2 (4%)	1 (2%)		1 (2%)
Artery, Inflammation				1 (2%)
Spleen	(50)	(50)	(50)	(50)
Atrophy			1 (2%)	
Hematopoietic Cell Proliferation	35 (70%)	35 (70%)	30 (60%)	34 (68%)
Hyperplasia, Lymphoid	8 (16%)	5 (10%)	11 (22%)	7 (14%)
Inflammation	1 (2%)			
Pigmentation	12 (24%)	8 (16%)	18 (36%)	7 (14%)
Thymus	(50)	(50)	(48)	(49)
Angiectasis		1 (2%)		
Atrophy		1 (2%)	1 (2%)	
Hemorrhage	1 (2%)			
Hyperplasia, Lymphoid	18 (36%)	21 (42%)	25 (52%)	22 (45%)
Inflammation			1 (2%)	

INTEGUMENTARY SYSTEM

Mammary Gland	(50)	(50)	(50)	(50)
Hyperplasia	5 (10%)	9 (18%)	3 (6%)	16 (32%)
Inflammation		2 (4%)		1 (2%)
Duct, Dilatation		1 (2%)		2 (4%)
Skin	(50)	(50)	(50)	(50)

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 99032 - 04
 Test Type: CHRONIC
 Route: SKIN APPLICATION
 Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)
 Pyrogallol
 CAS Number: 87-66-1

Date Report Requested: 08/17/2010
 Time Report Requested: 13:34:47
 First Dose M/F: 09/21/04 / 09/20/04
 Lab: BAT

B6C3F1 MICE FEMALE	0 MG/KG	5 MG/KG	20 MG/KG	75 MG/KG
Abscess		1 (2%)		
Fibrosis	1 (2%)	2 (4%)	1 (2%)	9 (18%)
Hyperkeratosis	1 (2%)	2 (4%)	1 (2%)	9 (18%)
Hyperplasia	1 (2%)	2 (4%)	1 (2%)	9 (18%)
Inflammation	1 (2%)			9 (18%)
Inflammation, Granulomatous		1 (2%)		
Pigmentation			1 (2%)	1 (2%)
Ulcer	1 (2%)	1 (2%)	1 (2%)	9 (18%)
Control, Hyperplasia				2 (4%)
Control, Inflammation	3 (6%)		1 (2%)	2 (4%)
Sebaceous Gland, Hyperplasia	1 (2%)		1 (2%)	7 (14%)
Sebaceous Gland, Site Of Application, Hyperplasia	1 (2%)	2 (4%)	6 (12%)	34 (68%)
Site Of Application, Cyst				1 (2%)
Site Of Application, Fibrosis	5 (10%)	6 (12%)	31 (62%)	49 (98%)
Site Of Application, Hyperkeratosis	24 (48%)	38 (76%)	49 (98%)	49 (98%)
Site Of Application, Hyperplasia	20 (40%)	31 (62%)	49 (98%)	49 (98%)
Site Of Application, Infiltration Cellular, Mast Cell			1 (2%)	1 (2%)
Site Of Application, Inflammation	12 (24%)	14 (28%)	42 (84%)	48 (96%)
Site Of Application, Pigmentation			35 (70%)	40 (80%)
Site Of Application, Ulcer	2 (4%)		3 (6%)	33 (66%)

MUSCULOSKELETAL SYSTEM

Bone	(50)	(50)	(50)	(50)
Fibro-Osseous Lesion	8 (16%)	9 (18%)	9 (18%)	2 (4%)
Skeletal Muscle	(4)	(1)	(2)	(0)
Inflammation	1 (25%)		1 (50%)	

NERVOUS SYSTEM

Brain	(50)	(50)	(50)	(50)
Developmental Malformation			1 (2%)	
Infiltration Cellular, Mononuclear Cell	1 (2%)	1 (2%)		

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 99032 - 04
 Test Type: CHRONIC
 Route: SKIN APPLICATION
 Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)
 Pyrogallol
 CAS Number: 87-66-1

Date Report Requested: 08/17/2010
 Time Report Requested: 13:34:47
 First Dose M/F: 09/21/04 / 09/20/04
 Lab: BAT

B6C3F1 MICE FEMALE	0 MG/KG	5 MG/KG	20 MG/KG	75 MG/KG
Inflammation	1 (2%)			1 (2%)
Cerebrum, Vacuolization Cytoplasmic			1 (2%)	
Peripheral Nerve	(2)	(0)	(0)	(0)
Sciatic, Atrophy	1 (50%)			
Sciatic, Infiltration Cellular, Mononuclear Cell	1 (50%)			
Spinal Cord	(2)	(0)	(0)	(0)
Atrophy	1 (50%)			
Degeneration	1 (50%)			
RESPIRATORY SYSTEM				
Lung	(50)	(50)	(50)	(50)
Fibrosis				1 (2%)
Infiltration Cellular, Histiocyte	2 (4%)	6 (12%)	2 (4%)	2 (4%)
Inflammation	3 (6%)	5 (10%)	1 (2%)	2 (4%)
Metaplasia, Osseous	2 (4%)			
Pigmentation	1 (2%)		1 (2%)	
Thrombosis	1 (2%)			
Artery, Mineralization	1 (2%)			
Bronchiole, Hyperplasia		1 (2%)		1 (2%)
Nose	(50)	(50)	(50)	(50)
Inflammation	13 (26%)	9 (18%)	17 (34%)	9 (18%)
Polyp, Inflammatory			1 (2%)	
Glands, Dilatation	2 (4%)			
Glands, Metaplasia	6 (12%)	7 (14%)	3 (6%)	7 (14%)
Olfactory Epithelium, Hyperplasia			1 (2%)	
Olfactory Epithelium, Metaplasia		3 (6%)	2 (4%)	2 (4%)
Respiratory Epithelium, Foreign Body			1 (2%)	
Respiratory Epithelium, Hemorrhage	1 (2%)		1 (2%)	
Respiratory Epithelium, Hyperplasia	46 (92%)	48 (96%)	46 (92%)	46 (92%)
Turbinate, Thrombosis	1 (2%)			
Trachea	(50)	(50)	(50)	(50)
Inflammation			1 (2%)	
Epithelium, Hyperplasia			1 (2%)	

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 99032 - 04
 Test Type: CHRONIC
 Route: SKIN APPLICATION
 Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)
 Pyrogallol
 CAS Number: 87-66-1

Date Report Requested: 08/17/2010
 Time Report Requested: 13:34:47
 First Dose M/F: 09/21/04 / 09/20/04
 Lab: BAT

B6C3F1 MICE FEMALE	0 MG/KG	5 MG/KG	20 MG/KG	75 MG/KG
SPECIAL SENSES SYSTEM				
Eye	(50)	(50)	(50)	(50)
Atrophy			1 (2%)	
Infiltration Cellular, Mononuclear Cell	1 (2%)	1 (2%)		1 (2%)
Inflammation	2 (4%)		1 (2%)	3 (6%)
Cornea, Hyperplasia	1 (2%)			
Retina, Angiectasis			1 (2%)	
Retina, Degeneration		1 (2%)		
Harderian Gland	(50)	(50)	(50)	(50)
Atrophy			1 (2%)	
Cyst	1 (2%)			
Hyperplasia	3 (6%)	9 (18%)	6 (12%)	5 (10%)
Infiltration Cellular, Mononuclear Cell	29 (58%)	33 (66%)	31 (62%)	24 (48%)
Inflammation	1 (2%)			
Mineralization				1 (2%)
Lacrimal Gland	(0)	(0)	(1)	(0)

URINARY SYSTEM

Kidney	(50)	(50)	(50)	(50)
Accumulation, Hyaline Droplet	2 (4%)	3 (6%)	2 (4%)	
Cyst			1 (2%)	
Dilatation		1 (2%)		2 (4%)
Infarct, Chronic			1 (2%)	
Infiltration Cellular, Mononuclear Cell	2 (4%)	5 (10%)	4 (8%)	4 (8%)
Inflammation	1 (2%)			3 (6%)
Metaplasia, Osseous	3 (6%)	1 (2%)	1 (2%)	2 (4%)
Mineralization	12 (24%)	7 (14%)	8 (16%)	7 (14%)
Nephropathy	33 (66%)	24 (48%)	28 (56%)	28 (56%)
Pigmentation	3 (6%)	1 (2%)	1 (2%)	
Papilla, Necrosis				1 (2%)
Renal Tubule, Degeneration	1 (2%)	1 (2%)	1 (2%)	
Renal Tubule, Hyperplasia	1 (2%)			
Renal Tubule, Vacuolization Cytoplasmic			1 (2%)	

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 99032 - 04
Test Type: CHRONIC
Route: SKIN APPLICATION
Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)
Pyrogallol
CAS Number: 87-66-1

Date Report Requested: 08/17/2010
Time Report Requested: 13:34:47
First Dose M/F: 09/21/04 / 09/20/04
Lab: BAT

B6C3F1 MICE FEMALE	0 MG/KG	5 MG/KG	20 MG/KG	75 MG/KG
Urinary Bladder	(50)	(50)	(50)	(50)
Infiltration Cellular, Mononuclear Cell	34 (68%)	37 (74%)	37 (74%)	42 (84%)
Inflammation	1 (2%)	1 (2%)	1 (2%)	1 (2%)

*** END OF REPORT ***

a - Number of animals examined microscopically at site and number of animals with lesion